The recent legalization of cannabis in Canada offers a unique opportunity to conduct fundamental research without the bureaucracy issues faced in other countries. The current state of cannabinoid (CB) based therapies have focused their use in the treatment of cancer, pain, inflammation and opioid addiction, and suffer from unwanted side effects and lack of efficacy. Our focus is on the development of new CB lead compounds that target the cannabinoid and related receptors (i.e. CB1, CB2, GPR55, opioid- and serotonin receptors).